Ansa Biotechnologies
Enzymatic synthesis of long, complex DNA
Ansa Biotechnologies (Emeryville, United States) — enzymatic synthesis of long, complex DNA. On November 18, 2026 it announced a $71.5M Series C, led by Blue Water Life Science Advisors. Oversubscribed. Total raised $211M. Prior: $54.4M Series B (Oct 2025). Funds go to manufacturing capacity.
Biotech
📍 Emeryville
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Ansa Biotechnologies going public?
No. Ansa Biotechnologies is private and has not filed to go public. There is no S-1 on file.
What is Ansa Biotechnologies' valuation in 2026?
No confirmed valuation is on record for Ansa Biotechnologies. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Ansa Biotechnologies filed an S-1?
No public S-1 is on file for Ansa Biotechnologies.
Who are Ansa Biotechnologies' investors?
Ansa Biotechnologies' investors include Blue Water Life Science Advisors.
How much has Ansa Biotechnologies raised?
Ansa Biotechnologies has raised $211M in total across 1 disclosed round, most recently a Series C of $71.5M in Nov 2026.
Is Ansa Biotechnologies publicly traded — can you buy Ansa Biotechnologies stock?
No. Ansa Biotechnologies is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Ansa Biotechnologies on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series C — $71.5M (Nov 2026) · Lead: Blue Water Life Science Advisors
Fundraising Status
Series C · $71.5M · this month
privateTotal raised $211M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series C | $71.5M | Nov 2026 | Blue Water Life Science Advisors | — |
Recent Activity
💰Nov 2026 · VentureBeat · funding
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Ansa Biotechnologies has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Ansa Biotechnologies has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Blue Water Life Science Advisors
BiotechEnzymatic DNA synthesis
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.